Licensee sought for non-toxigenic Clostridium difficile treatment and prevention technology
Dale Gerding, an infectious diseases specialist, researcher, professor and hospital epidemiologist, and one of the leading international experts on Clostridium difficile, has retained The Chicago Corporation to assist him in finding an exclusive licensee for his patented non-toxigenic Clostridium difficile (NTCD) technology for the prevention and treatment of Clostridium difficile infection.
Dr Gerding currently owns patents and all rights to the development, manufacturing, regulatory and clinical trial data for NTCD.
The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase I and II clinical trials, has US Food and Drug Administration fast-track approval status, and is expected to be eligible for Breakthrough Therapy designation by the FDA for a Phase III Trial and to be eligible for reference product exclusivity for 12 years for an approved biologics license application.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze